Skip to content
Open access · OA via Europe PMC

Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes.

Yanai H, Adachi H, Hakoshima M, Katsuyama H.

Journal of clinical medicine research · 2025 · ▲ 1 citations

Abstract

Aging is a complicated biological process that induces a decline in the human organs' structure and function and elevates the risks of aging-related diseases such as Alzheimer's disease (AD) and type 2 diabetes. Type 2 diabetes accelerates all clinical manifestations of aging. Metabolic disorders in type 2 diabetes are unfavorably associated with all telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition), such as inflammation and mitochondrial dysfunction(definition). Adenosine monophosphate-activated protein kinase (AMPK) and the mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) complex 1 (mTORC1) are key players in cellular metabolism, and AMPK activation and mTORC1 inhibition improve all hallmarks of aging. AMPK activation and mTORC1 inhibition are favorably associated with diabetic complications. Nutritional interventions, such as caloric restriction(definition), resveratrol, and astaxanthin, have AMPK-activating and mTORC1-inhibitory effects and improve metabolic abnormalities in type 2 diabetes. Anti-diabetic drugs, metformin, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide 1 receptor agonists have been reported to have AMPK-activating and mTORC1-inhibiting effects and show prevention of aging-related diseases such as cardiovascular disease. The therapeutic interventions that activate AMPK and inhibit mTORC1 may be optimal treatments for type 2 diabetes from the perspective of anti-aging medicine. Furthermore, senolytics(definition) may be a promising, direct anti-aging therapeutic strategy specifically for type 2 diabetes and its complications.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.14740/jocmr6370
Canonical
link ↗
Fetched
2026-07-01 MST

Cite this

APA
H, Y., H, A., M, H., &amp; H., K. (2025). Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes. <em>Journal of clinical medicine research</em>. https://doi.org/10.14740/jocmr6370
Vancouver
H Y, H A, M H, H. K. Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes. Journal of clinical medicine research. 2025. doi:10.14740/jocmr6370.
BibTeX
@article{yanai2025Adenos, title = {Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes.}, author = {Yanai H and Adachi H and Hakoshima M and Katsuyama H.}, journal = {Journal of clinical medicine research}, year = {2025}, doi = {10.14740/jocmr6370}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings